Home › Hemophilia › Illinois › Chicago
Hemophilia clinical trials in Chicago, IL
3 studies for Hemophilia are looking for participants at sites in and around Chicago (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
RecruitingObservational study
- Rush University Medical Center, Chicago
Prevention of Bleeding in Patients With Moderate and Severe Hemophilia A Playing Sports: A Comparison Between Factor VIII and Emicizumab Prophylaxis
RecruitingObservational study
- Rush University Children's Hospital, Chicago
A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)
RecruitingPhase 1Healthy volunteers welcome
- Rush University Medical Center, Chicago
About Hemophilia
Hemophilia is a rare disorder in which the blood does not clot normally. Usually hemophilia usually occurs in males and is inherited. Learn more.
More about Hemophilia on MedlinePlus
Hemophilia trials in other cities
- Indianapolis, IN9 studies
- Seattle, WA8 studies
- Cedar Rapids, IA7 studies
- Los Angeles, CA6 studies
- Philadelphia, PA6 studies
- Dallas, TX5 studies
- Little Rock, AR5 studies
- San Antonio, TX5 studies
- Sacramento, CA5 studies
- Ann Arbor, MI4 studies
- Orange, CA4 studies
- Tampa, FL4 studies
Other studies in Chicago
- Breast Cancer59 studies
- Non-Small Cell Lung Cancer59 studies
- Cancer (all types)51 studies
- Prostate Cancer45 studies
- Lung Cancer43 studies
- Metastatic Cancer42 studies
- Obesity40 studies
- Ovarian Cancer36 studies
- Colorectal Cancer32 studies
- Stroke31 studies
- Head and Neck Squamous Cell Carcinoma29 studies
- Overweight29 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.